Current state of proton therapy for tumors of the central nervous system in Spain: physical bases, indications, controversies and perspectives
-
Eva María Corrales García [1] ; José Javier Aristu Mendioroz [2] ; Juan Castro Novais [3] ; Raúl Matute Martín [4] ; María Concepción Learra Martínez [5] ; Pedro David Delgado López [1]
-
[1] Complejo Asistencial Universitario de Burgos
Complejo Asistencial Universitario de Burgos
Burgos, España
-
[2] Clínica Universitaria de Navarra
Clínica Universitaria de Navarra
Pamplona, España
-
[3] Servicio de Radiofísica y Protección Radiológica, Centro de Protonterapia. Hospital Universitario Quironsalud, Madrid, Spain
-
[4] Servicio Oncología Radioterápica, Centro de Protonterapia, Hospital Quironsalud, Madrid, Spain
-
[5] Comisión de Protonterapia de La Comunidad de Castilla y LeónServicio de Atención Hospitalaria y CoordinaciónDirección Técnica de Asistencia SanitariaDirección General de Asistencia Sanitaria y HumanizaciónGerencia Regional de Salud de Castilla y León, Valladolid, Spain
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 3, 2025, págs. 858-870
- Idioma: inglés
- Títulos paralelos:
- Estado actual de la terapia con protones en los tumores del sistema nervioso central en España: bases físicas, indicaciones, controversias y perspectivas
- Texto completo no disponible (Saber más ...)
-
Resumen
The unique biophysical properties of proton therapy (PT), regarding the precise dose distribution, a remarkable better sparing of surrounding normal tissues, and the decreasing costs have promoted the spread of this technique worldwide. In Spain, eleven new PT centers, added to the currently two in function, are expected to be available in the near future. Indications for PT are currently evolving. The suitability of PT in central nervous system tumors of the adult population has been extrapolated from the favorable experience in children and adolescents. Given the lack of appropriate randomized trials, controversies remain regarding its use in lower grade tumors, re-irradiation, and other clinical scenarios in which an a priori dose distribution beneft is expected compared to photon-based radiotherapy. PT is a reasonable option in many brain and spinal tumors associating long life expectancy, in which cognitive decline, and the appearance of radiation-induced neoplasms can be minimized.
